-

Company Profile for bioAffinity Technologies, Inc.

--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology are conducted in bioAffinity Technologies’ laboratories at the University of Texas San Antonio (UTSA). The Company’s platform technology is being developed to diagnose, monitor and treat many cancers.

Company:

bioAffinity Technologies, Inc.

 

 

Headquarters Address:

22211 W I-10, Suite 1206

 

San Antonio, TX 78257

 

 

Main Telephone:

5054009747

 

 

Website:

www.bioaffinitytech.com

 

 

Type of Organization:

Private

 

 

Industry:

Biotechnology

 

 

Key Executives:

CEO: Maria Zannes

 

 

Public Relations

 

Contact:

Julie Anne Overton

Phone:

5055770918

Email:

jaoverton@mac.com

 

bioAffinity Technologies, Inc.

NASDAQ:BIAF
Details
Headquarters: San Antonio, TX
CEO: Maria Zannes
Employees: 52
Organization: PUB

Release Versions

More News From bioAffinity Technologies, Inc.

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity and Pictor partner to advance next-generation lung inflammation diagnostics for asthma and COPD for personalized treatment....

bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technology reports continued acceleration in commercial sales for its CyPath® Lung diagnostic with more than 200% growth year-over-year....

bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies reports on preclinical findings that demonstrate siRNA therapy kills skin cancer cells while sparing healthy cells....
Back to Newsroom